Feminai, an Israeli company developing wearable technology for breast cancer detection, has raised $6 million in seed funding. The round was led by Vertex Ventures Israel with participation from ICI Fund, Fusion VC, Arben Ventures, Cactus Capital, and angel investor Mark Zitter.
The company is developing a wearable device that uses sensors to track breast density and blood flow changes, combined with AI analysis, to detect breast cancer. Feminai’s approach is designed to enable at-home screening without the need for clinic visits.
Feminai has completed its first in-human clinical trial at Sheba Medical Center in Israel. The company reports the technology achieved 96% sensitivity and 98% negative predictive value (NPV).
“This funding will allow us to strengthen our team and accelerate our path toward regulatory approval and market entry,” said Karny Ilan, MD, Co-founder and CEO of Feminai. “Our goal is to make breast cancer screening more accurate, accessible, and affordable—ultimately improving outcomes for women’s health.”
The funding will support team expansion, regulatory efforts, and go-to-market preparation.
Feminai was co-founded by Ilan, who is also a physician at Sheba Medical Center, alongside Gal Yanuka and Shani Klein.
